N
Narsimha Reddy Penthala
High Impact
Instructor
faculty
Pharmaceutics, College of Pharmacy
23 h-index
159 pubs
1,410 cited
Research Areas
Biography and Research Information
OverviewAI-generated summary
Narsimha Reddy Penthala is an instructor in Pharmaceutics at the University of Arkansas for Medical Sciences. His research interests include the investigation of novel therapeutic agents for various diseases, with a focus on cancer, neurodegenerative disorders, and bone/kidney toxicity.
Penthala has published research on the antitumor properties of sesquiterpene lactone analogs, exploring their potential as NFκB inhibitors. He has also investigated the use of hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer's disease and the efficacy of thiadiazolidinone (TDZD) analogs in inhibiting aggregation-mediated pathology in neurodegeneration models. His work extends to evaluating the toxicity of drug carriers, such as BT2-peg2 for targeted antibiotic delivery to bone, and pharmacokinetic studies of compounds like morphine-6-O-sulfate.
His recent publications include work on biobanked glioblastoma patient-derived organoids as a model for precision medicine and studies on the pharmacological dual inhibition of tumor and tumor-induced functional limitations in a transgenic breast cancer model. Penthala leads a research group and has a scholarly output characterized by 159 publications and 1,385 citations, with an h-index of 23. He collaborates with researchers at the University of Arkansas for Medical Sciences, including Peter A. Crooks and Meenakshisundaram Balasubramaniam.
Metrics
- h-index: 23
- Publications: 159
- Citations: 1,410
Selected Publications
-
Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend C. elegans Life- and Healthspan (2023)
-
Table S2 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer (2023)
-
Biobanked Glioblastoma Patient-Derived Organoids as a Precision Medicine Model to Study Inhibition of Invasion (2021)
-
Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer’s disease (2021)
-
Antitumor properties of novel sesquiterpene lactone analogs as NFκB inhibitors that bind to the IKKβ ubiquitin-like domain (ULD) (2021)
-
Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone (2021)
-
A pharmacokinetic study of <scp>morphine‐6‐<i>O</i></scp>‐sulfate in rat plasma and brain (2021)
Grants & Funding
- Enhancing the prevention and treatment of orthopaedic infections associated with traumatic injury US Department of Defense Co-Investigator
- Development of Small Molecule Radiation Sensitizers NIH/Nat. Cancer Institute - Pass Through: Vanderbilt University Co-Investigator
- Development of Novel Therapeutics for Methamphetamine Abuse - Continuation NIH/Nat. Inst. on Drug Abuse - Pass Through: University of Kentucky Research Foundation Co-Investigator
- Early Events in Alzheimer Pathogenesis NIH Co-Investigator
- Novel melampomagnolide B-based prodrugs for the treatment of leukemia NIH Co-Investigator
Collaboration Network
Top Collaborators
Peter A. Crooks
16 shared publications
In database
- Biobanked Glioblastoma Patient-Derived Organoids as a Precision Medicine Model to Study Inhibition of Invasion
- Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer’s disease
- Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend C. elegans Life- and Healthspan
- Antitumor properties of novel sesquiterpene lactone analogs as NFκB inhibitors that bind to the IKKβ ubiquitin-like domain (ULD)
- Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone
Showing 5 of 16 shared publications
Poornima Bhat‐Nakshatri
11 shared publications
- Antitumor properties of novel sesquiterpene lactone analogs as NFκB inhibitors that bind to the IKKβ ubiquitin-like domain (ULD)
- Figure S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S3 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S2 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
Showing 5 of 11 shared publications
Harikrishna Nakshatri
11 shared publications
- Antitumor properties of novel sesquiterpene lactone analogs as NFκB inhibitors that bind to the IKKβ ubiquitin-like domain (ULD)
- Figure S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S3 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S2 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
Showing 5 of 11 shared publications
Ruizhong Wang
10 shared publications
- Figure S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S3 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S2 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Figure S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
Showing 5 of 10 shared publications
Mayuri S Prasad
10 shared publications
- Figure S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S3 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S2 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Figure S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
Showing 5 of 10 shared publications
Manjushree Anjanappa
10 shared publications
- Figure S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S3 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S2 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Figure S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
Showing 5 of 10 shared publications
Max E. Jacobson
10 shared publications
- Figure S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S3 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S2 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Figure S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
Showing 5 of 10 shared publications
Courtney Finnearty
10 shared publications
- Figure S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S3 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S2 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Figure S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
Showing 5 of 10 shared publications
Victoria Sefcsik
10 shared publications
- Figure S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S3 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S2 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Figure S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
Showing 5 of 10 shared publications
Kyle McElyea
10 shared publications
- Figure S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S3 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S2 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Figure S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
Showing 5 of 10 shared publications
Rachael Redmond
10 shared publications
- Figure S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S3 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S2 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Figure S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
Showing 5 of 10 shared publications
George E. Sandusky
10 shared publications
- Figure S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S3 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S2 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Figure S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
Showing 5 of 10 shared publications
Teresa A. Zimmers
10 shared publications
- Figure S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S3 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S2 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Figure S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
Showing 5 of 10 shared publications
Maria B. Padua
6 shared publications
- Table S3 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Figure S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S3 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
Showing 5 of 6 shared publications
Maria B. Padua
4 shared publications
- Figure S1 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S2 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Table S2 from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Data from Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
Similar Researchers
Based on overlapping research topics
Zaineb A.F. Albayati
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Neuroscience and Neuropharmacology Research
Nanoparticle-Based Drug Delivery
Tra Le
Arkansas State University
Cancer Treatment and Pharmacology
Pharmacological Effects and Toxicity Studies
Cancer-related molecular mechanisms research
Elizabeth A Duplechain
Arkansas State University
Neurological disorders and treatments
Pharmacological Effects and Toxicity Studies
Neuroscience and Neuropharmacology Research
Leila Bagherzadeh
University of Arkansas for Medical Sciences
Neurological disorders and treatments
Pharmacological Effects and Toxicity Studies
Neuroscience and Neuropharmacology Research
Fang Liu
National Center for Toxicological Research
Cancer Treatment and Pharmacology
Neurological disorders and treatments
Pharmacological Effects and Toxicity Studies
Daniel Fil
University of Arkansas for Medical Sciences
Neurological disorders and treatments
Pharmacological Effects and Toxicity Studies
Neuroscience and Neuropharmacology Research